Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations

In this Ph II study glesatinib (MET and AXL inhibitor) had acceptable safety but modest activity in NSCLC cohorts with MET dysregulation

Source: Lung Cancer - February 22, 2024 Category: Cancer & Oncology Authors: David S. Hong, Federico Cappuzzo, Byoung Chul Cho, Afshin Dowlati, Maen Hussein, Dong-Wan Kim, Ivor Percent, James G. Christensen, Jos ée Morin, Diane Potvin, Demiana Faltaos, Vanessa Tassell, Hirak Der-Torossian, Richard Chao Source Type: research